Hepatitis B and Hepatitis C Infection Biomarkers and TP53 Mutations in Hepatocellular Carcinomas from Colombia.

Maria-Cristina Navas (1) , Iris Suarez (1) , Andrea Carreño (1) , Diego Uribe (1) , Wilson Alfredo Rios (1) , Fabian Cortes-Mancera (1) , Ghyslaine Martel (2) , Beatriz Vieco (1) , Diana Lozano (1) , Carlos Jimenez (1, 3) , Doriane Gouas (2) , German Osorio (1) , Sergio Hoyos (1) , Juan Carlos Restrepo (1) , Gonzalo Correa (1) , Sergio Jaramillo (4) , Rocio Lopez (1) , Luis Eduardo Bravo (1) , Maria Patricia Arbelaez (1) , Jean-Yves Scoazec (5) , Behnoush Abedi-Ardekani (1) , Regina M Santella (6) , Isabelle Chemin (5) , Pierre Hainaut (7)

1 Universidad de Antioquia = University of Antioquia [Medellín, Colombia]
2 Centre Léon Bérard [Lyon]
3 CIMAR - Centro de Investigación en Ciencias del Mar y Limnología
4 Hospital pablo Tobon
5 UNICANCER/CRCL - Centre de Recherche en Cancérologie de Lyon
6 Colombia University
7 Sect Mech Carcinogenesis

Hepatocellular Carcinoma (HCC) is a leading cause of cancer-related death worldwide. Globally, the most important HCC risk factors are Hepatitis B Virus (HBV) and/or Hepatitis C Virus (HCV), chronic alcoholism, and dietary exposure to aflatoxins. We have described the epidemiological pattern of 202 HCC samples obtained from Colombian patients. Additionally we investigated HBV/HCV infections and TP53 mutations in 49 of these HCC cases. HBV biomarkers were detected in 58.1% of the cases; HBV genotypes F and D were characterized in three of the samples. The HCV biomarker was detected in 37% of the samples while HBV/HCV coinfection was found in 19.2%. Among TP53 mutations, 10.5% occur at the common aflatoxin mutation hotspot, codon 249. No data regarding chronic alcoholism was available from the cases. In conclusion, in this first study of HCC and biomarkers in a Colombian population, the main HCC risk factor was HBV infection.

Domaines: Cancer

Maria-Cristina Navas, Iris Suarez, Andrea Carreño, Diego Uribe, Wilson Alfredo Rios, et al.. Hepatitis B and Hepatitis C Infection Biomarkers and TP53 Mutations in Hepatocellular Carcinomas from Colombia.. Hepatitis Research and Treatment, 2011, 2011, pp.582945. ⟨10.1155/2011/582945⟩. ⟨hal-00855692⟩